Revolution Medicines, Inc. (RVMDW) stock
RVMDWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMD
$9.81+0.18 (+1.82%)
Close on Oct 30, 2026Market cap $41.00BP/E –Yield –
Revolution Medicines free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Revolution Medicines's free cash flow for the twelve months ending Jun 30, 2026 was -$1.23B. For fiscal 2025 it was -$913.73M. The highest annual figure on record is -$286.00K in fiscal 2018.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$913.73M | – |
| FY2024 | Dec 31, 2024 | -$567.74M | – |
| FY2023 | Dec 31, 2023 | -$358.30M | – |
| FY2022 | Dec 31, 2022 | -$235.22M | – |
| FY2021 | Dec 31, 2021 | -$153.71M | – |
| FY2020 | Dec 31, 2020 | -$103.00M | – |
| FY2019 | Dec 31, 2019 | -$52.21M | – |
| FY2018 | Dec 31, 2018 | -$286.00K | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$389.61M | – |
| Q1 FY2026 | Mar 31, 2026 | -$355.70M | – |
| Q4 FY2025 | Dec 31, 2025 | -$276.16M | – |
| Q3 FY2025 | Sep 30, 2025 | -$210.66M | – |
| Q2 FY2025 | Jun 30, 2025 | -$229.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$197.70M | – |
| Q4 FY2024 | Dec 31, 2024 | -$139.51M | – |
| Q3 FY2024 | Sep 30, 2024 | -$133.94M | – |
| Q2 FY2024 | Jun 30, 2024 | -$130.57M | – |
| Q1 FY2024 | Mar 31, 2024 | -$163.73M | – |
| Q4 FY2023 | Dec 31, 2023 | -$122.88M | – |
| Q3 FY2023 | Sep 30, 2023 | -$103.03M | – |
| Q2 FY2023 | Jun 30, 2023 | -$68.24M | – |
| Q1 FY2023 | Mar 31, 2023 | -$64.15M | – |
| Q4 FY2022 | Dec 31, 2022 | -$64.66M | – |
| Q3 FY2022 | Sep 30, 2022 | -$55.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$58.24M | – |
| Q1 FY2022 | Mar 31, 2022 | -$57.05M | – |
| Q4 FY2021 | Dec 31, 2021 | -$40.45M | – |
| Q3 FY2021 | Sep 30, 2021 | -$37.04M | – |
| Q2 FY2021 | Jun 30, 2021 | -$35.39M | – |
| Q1 FY2021 | Mar 31, 2021 | -$40.83M | – |
| Q4 FY2020 | Dec 31, 2020 | -$26.20M | – |
| Q3 FY2020 | Sep 30, 2020 | -$27.71M | – |
| Q2 FY2020 | Jun 30, 2020 | -$20.47M | – |
| Q1 FY2020 | Mar 31, 2020 | -$28.62M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.16M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.96M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.13M | – |
| Q1 FY2019 | Mar 31, 2019 | -$12.95M | – |